Ryan Russell
Optometrist · Tupelo, MSNPI 1831180900
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 25.3% of the total. Reporting peaked in 2022 at $1,213 and has fallen 58.8% since, to $500 in 2025. Among optometrist clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $25.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$1K
- Alcon$1K
- Johnson & Johnson Vision Care, Inc.$781
- Bausch & Lomb, A Division Of Bausch Health US, LLC$566
- Sun Pharmaceutical Industries Inc.$233
- AbbVie$190
- plus $874 from 11 others
What the payments were for
- Food & beverage$5,00698%
- Entertainment$1242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 63 | $1,297 |
| Alcon | 27 | $1,189 |
| Johnson & Johnson Vision Care, Inc. | 36 | $781 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 33 | $566 |
| Sun Pharmaceutical Industries Inc. | 7 | $233 |
| AbbVie(2 entities) | 11 | $190 |
| Coopervision Inc. | 4 | $146 |
| Oyster Point Pharma, Inc. | 7 | $138 |
| Optos, Inc. | 1 | $124 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $121 |
| Rxsight Inc | 2 | $105 |
| Integra Lifesciences Corporation | 1 | $84 |
| Mallinckrodt Hospital Products Inc. | 3 | $55 |
| Eyevance Pharmaceuticals LLC | 2 | $34 |
| Carl Zeiss Meditec USA, Inc. | 1 | $28 |
| Tarsus Pharmaceuticals, Inc. | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANORAMIC OPHTHALMOSCOPE$249
- OCT OPHTHALMOSCOPE$249
- NFC-700$124
- CEQUA$123
- Catalys Laser System$121
- TOTAL30$108
- Acuvue$103
How this compares
$5,130 in reported general payments places this provider in the 90th percentile of 372 optometrist providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 61 | $19,326 |
| RestasisCyclosporine | 20 | $18,819 |
| VyzultaLatanoprostene Bunod | 16 | $4,016 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 50 | $1,975 |
| Latanoprost | 294 | $1,825 |
| Brimonidine Tartrate | 35 | $1,460 |
| Prednisolone Acetate | 39 | $1,160 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 51 | $1,065 |
| Azelastine Hcl | 18 | $453 |
| Dorzolamide Hcl | 27 | $385 |
| Timolol Maleate | 40 | $216 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 21 | $202 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $173 |
| Ciprofloxacin Hcl | 12 | $144 |
| Cephalexin | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis | $190 | $38,14581 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $1,297 | $4,01616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 372 optometrist providers in Mississippi.
Other optometrist in Tupelo
- Dax EckardTupelo$5K
- Chelsea McKnightTupelo$4K
- Fred MothershedTupelo$4K
- Kristopher MayColdwater$229K
- Alyssa MabrySenatobia$66K
- Roya AttarJackson$19K
- Deandre CarrByram$9K
- Michael ObrienSouthaven$9K
- George MarchbanksGulfport$9K
- William ArnoldMadison$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.